Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 40Carcinoma, Non-Small-Cell Lung 32Colorectal Neoplasms 27Ovarian Neoplasms 23Neoplasms 23Lung Neoplasms 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Pancreatic Neoplasms 17Leukemia, Myeloid, Acute 16Head and Neck Neoplasms 16Lymphoma, Non-Hodgkin 15Neoplasm Metastasis 14Fallopian Tube Neoplasms 14Glioblastoma 13Esophageal Neoplasms 12Rectal Neoplasms 11Lymphoma 11Squamous Cell Carcinoma of Head and Neck 10Central Nervous System Neoplasms 10Carcinoma, Ovarian Epithelial 10Recurrence 9Melanoma 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Follicular 9Leukemia 9Stomach Neoplasms 8Prostatic Neoplasms 8Lymphoma, Mantle-Cell 7Lymphoma, B-Cell, Marginal Zone 7Liver Neoplasms 7

Interventions

pegfilgrastim 5NPI 2358 3balugrastim 2Granulocyte Colony-Stimulating Factor 2Drug Therapy 2Doxorubicin 2Docetaxel 2Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Chemotherapy-induced Neutropenia × Drug Therapy × Clear all
NCT00837265 2024-04-03

NEUGR-002

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2/3 Completed
334 enrolled 16 charts

Chemotherapy-induced Neutropenia

NCT01126190 2023-03-28

NEUGR-003

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 3 Completed
381 enrolled 13 charts

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡